Molecular pathology of cyclooxygenase-2 in neoplasia

Annals of Clinical and Laboratory Science

Volumn 30, Issue 1, 2000, Pages 3-21

  Fosslien, Egil ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Angiogenesis; Antioxidants; Apoptosis; Cancer invasion; Carcinogenesis; Cyclooxygenase 2; Metastasis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; ARACHIDONIC ACID; BENZO[A]PYRENE; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; IBUPROFEN; INDOMETACIN; INTERLEUKIN 1; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; PROTEIN BCL 2; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; CANCER INHIBITION; CANCER INVASION; GENE ACTIVATION; GENE INDUCTION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; METASTASIS; NEOPLASM; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW;

ANIMALS; CARCINOMA, SQUAMOUS CELL; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SKIN NEOPLASMS;

EID: 0033973713     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (160)

1. Garay CA, Engstrom PF. Chemoprevention of colorectal cancer: dietary and pharmacologic approaches. Oncology 1999; 13:89-98.
2. Sandler RS. Epidemiology and risk factors for colorectal cancer. Gastroenterol Clin North Am 1996; 25:717-735.
3. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231:232-235.
4. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28:67-81.
5. Schapira DV, Theodossiou C, Lyman GH. The effects of NSAIDs on breast cancer prognostic factors. Oncol Rep 1999; 6:433-435.
6. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology 1996; 7:203-205.
7. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999; 6:71-73.
8. Farrow DC, Vaughan TL, Hansten PD, Stanford JL, Risch HA, Gammon MD, Chow WH, Dubrow R, Ahsan H, Mayne ST, Schoenberg JB, West AB, Rotterdam H, Fraumeni JF Jr, Blot W. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998; 7:97-102.
9. Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997; 39:1-20.
10. Smalley W, Ray WA, Daughterly J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med 1999; 159:161-166.
11. Ahnen DJ. Multi-phase chemoprevention of large bowel carcinogenesis. Am J Gastroenterol 1993; 88:1647-1649.
12. Cibere J, Sibley J, Haga M. Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997; 40:1580-1586.
13. Thun MJ. Aspirin and gastrointestinal cancer. Adv Exp Med Biol 1997; 400A:395-402.
14. Weiss HA, Forman D. Aspirin, nonsteroidal anti-inflammatory drugs and protection from colorectal cancer: a review of epidemiological evidence. Scand J Gastroenterol Suppl 1996; 220:137-141.
15. Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians Health Study. Ann Intern Med 1998; 128:713-720.
16. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998; 351:104-107.
17. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancer of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998; 7:869-873.
18. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, Sakamaki S, Kato J, Kogawa K, Miyake H, Niitsu Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998; 339:1277-1284.
19. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD. G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 1996; 56:733-737.
20. Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 1998; 13:591-597.
21. Winde G, Schmid KW, Brandt B, Muller O, Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997; 40:1156-1169.
22. DuBois RN, Giardiello FM, Smalley WE. Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am 1996; 25:773-791.
23. Vane JR, Botting RM. Mechanism of action of aspirin-like drugs. Semin Arthritis Rheum 1997; 26:2-10.
24. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104:413-421.
25. Wolff H, Saukkonen K, Anttila S, Karjalainen A, Vainio H, Ristimaki A. Expression of cyclo-oxygenase-2 in human lung carcinoma. Cancer Res 1998; 58:4997-5001.
26. Koga H, Sakisaka S, Ohishi M, Kawaguchi T, Taniguchi E, Sasatomi K, Harada M, Kusaba T, Tanaka M, Kimura R, Nakashima Y, Nakashima O, Kojiro M, Kurohiji T, Sata M. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 1999; 29:688-696.
27. Shiota G, Okubo M, Noumi T, Noguchi N, Oyama K, Takano Y, Yashima K, Kishimoto Y, Kawasaki H. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46:407-412.
28. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19:723-729.
29. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.
30. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Kato H, Kondo M, Hla T. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995; 55:3785-3789.
31. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999; 59:198-204.
32. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, Sugihara K. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 1998; 58:4823-4826.
33. Sakuma K, Fujimore T, Hirabayashi K, Terano A. Cyclooxygenase (COX)-2 immunoreactivity and relationship to p53 and Ki-67 expression in colorectal cancer. J Gastroenterol 1999; 34:189-194.
34. Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Robinson CR, Hubbard WC, Hamilton SR, Yang VW. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci 1998; 43:311-316.
35. Berg J, Christoph T, Bodenteich A, Towart R. Heterogeneous distribution of COX-2 over-expression in human colon carcinoma cells. Adv Exp Med Biol 1997; 433:327-330.
36. Fingleton BM, Heppner Goss KJ, Crawford HC, Matrisian LM. Matrilysin in early stage intestinal tumorigenesis. APMIS 1999; 107:102-110.
37. Shattuck-Brandt RL, Lamps LW, Heppner Goss KJ, DuBois RN, Matrisian EM. Differential expression of matrilysin and cyclooxygenase-2 in intestinal and colorectal neoplasms. Mol Carcinog 1999; 24:177-187.
38. Cardillo MR, Yap E. TGF-beta1 in colonic neoplasia: a genetic molecular and immunohistochemical study. J Exp Clin Cancer Res 1997; 16:281-288.
39. Shao J, Sheng H, Aramandla R, Pereira MA, Lubet RA, Hawk E, Grogan L, Kirsch IR, Washington MK, Beauchamp RD, DuBois RN. Coordinate regulation of cyclooxygenase-2 and TGF-beta-1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999; 20:185-191.
40. A very A, Paraskeva C, Hall P, Flanders KC, Sporn M, Moorghen M. TGF-beta expression in the human colon: differential immunostaining along crypt epithelium. Br J Cancer 1993; 68:137-139.
41. Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:549-554.
42. Rao CV, Kawamori T, Hamid R, Reddy BS. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999; 20:641-644.
43. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90:455-460.
44. Jun SS, Chen Z, Pace MC, Shaul PW. Estrogen upregulates cyclooxygenase-1 gene expression in ovine fetal pulmonary artery endothelium. J Clin Invest 1998; 102:176-183.
45. Chakraborty I, Das SK, Wang J, Dey SK. Developmental expression of the cyclo-oxygenase-1 and cyclo-oxygenase-2 genes in the peri-implantation mouse uterus and their differential regulation by the blastocyst and ovarian steroids. J Mol Endocrinol 1996; 16:107-122.
46. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89:7384-7388.
47. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38:97-120.
48. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88:2692-2696.
49. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991; 15:12866-12872.
50. O'Banion MK, Sadowski HB, Winn V, Young DA. A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 1991; 266:23261-23267.
51. Hla T. Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript. Prostaglandins 1996; 51:81-84.
52. Appleby SB, Ristimaki A, Neilson K, Narko K, Hla T. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302:723-727.
53. Wallace AD, Wheeler TT, Young DA. Inducibility of E4BP4 suggests a novel mechanism of negative gene regulation by glucocorticoids. Biochem Biophys Res Commun 1997; 232:403-406.
54. Morisset S, Patry C, Lora M, de Brum-Fernandes J. Regulation of cyclooxygenase-2 expression in bovine chondrocytes in culture by interleukin 1 alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol. J Rheumatol 1998; 25:1146-1153.
55. Ristimaki A, Garfinkel S, Wessendorf J, Maciag T, Hla T. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem 1994; 269:11769-11775.
56. Huang JC, Liu DY, Yadollahi S, Wu KK, Dawood MY. Interleukin-1 beta induces cyclooxygenase-2 gene expression in cultured endometrial stromal cells. J Clin Endocrinol Metab 1998; 83:538-541.
57. Crofford LJ, Tan B, McCarthy CJ, Hla T. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2-expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum 1997; 40:2226-2236.
58. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997; 272:601-608.
59. Perkins DJ, Kniss DA. Rapid and transient induction of cyclooxygenase 2 by epidermal growth factor in human amnion-derived WISH cells. Biochem J 1997; 321:677-681.
60. Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, Moch H, Gudat F, Mihatsch MJ, Waldman F. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer 1994; 57:508-514.
61. Radinsky R, Risin, Fan, Dong, Bielenberg, Bucana, Fidler. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995; 1:19-31.
62. Wang Y, Minoshima S, Shimizu N. Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved FISH technique. Jpn J Hum Genet 1993; 38:399-406.
63. Jolly C, Michelland S, Rocchi M, Robert-Nicoud M, Vourc'h C. Analysis of the transcriptional activity of amplified genes in tumour cells by fluorescence in situ hybridization. Hum Genet 1997; 101:81-87.
64. Kawasaki K, Kudoh J, Omoto K, Shimizu N. Mega base map of the epidermal growth factor (EGF) receptor gene flanking regions and structure of the amplification units in EGF receptor-hyperproducing squamous carcinoma cells. Jpn J Cancer Res 1988 ; 79:1174-1183.
65. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997; 57:2890-2895.
66. Wang HM, Rajagopal S, Chakrabarty S. Inhibition of human colon cancer malignant cell behavior and growth by antisense epidermal growth factor receptor expression vector. Anticancer Res 1998; 18:2297-2300.
67. Jenson HB, Leach CT, McClain KL, Joshi W, Pollock BH, Parmley RT, Chadwick EG, Murphy SB. Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. Leuk Lymphoma 1997; 27:303-314.
68. Jimenez-Heffernan JA, Hardisson D, Palacios J, Garcia-Viera M, Gamallo C, Nistal M. Adrenal gland leiomyoma in a child with acquired immunodeficiency syndrome. Pediatr Pathol Lab Med 1995; 15:923-929.
69. de Chadarevian JP, Wok JH, Innis S, Lischner HW, d'Amore F, Faerber EN, Isaacson GC. A newly recognized cause of wheezing: AIDS-related bronchial leiomyomas. Pediatr Pulmonol 1997; 24:106-110.
70. Kleinschmidt-DeMasters BK, Mierau GW, Sze CI, Breeze RE, Greffe B, Lillehei KO, Stephens JK. Unusual dural and skull-based mesenchymal neoplasms: a report of four cases. Hum Pathol 1998; 29:240-245.
71. Prevot S, Neris J, de Saint Maur PP. Detection of Epstein-Barr virus in an leiomyomatous neoplasm in an adult immunodeficiency virus 1-infected patient. Virchows Arch 1994; 425:321-325.
72. Davidoff AM, Hebra A, Clark BJ III, Tomaszewski JE, Montone KT, Ruchelli E, Lau HT. Epstein-Barr virus -associated hepatic smooth muscle neoplasm in a cardiac transplant patient. Transplantation 1996; 61:515-517.
73. Longnecker R, Kieff E. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol 1990; 64:2319-2326.
74. Longnecker R. Biochemical and genetic studies of Epstein-Barr virus latent membrane protein 2. Leukemia 1994; 8 (Suppl 1): S46-50.
75. Sample J, Liebowitz D, Kieff E. Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol 1989:; 63:933-937.
76. Miller WE, Earp HS, Raab-Traub N. The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995; 69:4390-4398.
77. Spender LC, Cannell EJ, Hollyoake M, Wensing B, Gawn JM, Brimmell M, Packham G, Farrell PJ. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol 1999; 73:4678-4688.
78. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois, Beauchamp RD. Cyclooxygenase-2 induction and transforming growth factor beta growth inhibition in rat intestinal epithelial cells. Cell Growth Differ 1997; 8:463-470.
79. Diaz A, Chepenik KP, Korn JH, Reginato AM, Jimenez SA. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human fibroblasts. Exp Cell Res 1998; 241:222-229.
80. Oft M, Heider KH, Beug H. TGF-beta signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998; 8:1243-1252.
81. Akiyama Y, Iwanaga R, Saitoh K, Shiba K, Ushio K, Ikeda E, Iwama T, Nomizu T, Yuasa Y. Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer. Gastroenterology 1997; 112:33-39.
82. Kim Y, Fischer SM. Transcriptional regulation of cyclooxygenase-2 in mouse skin carcinoma cells: Regulatory role of CCAAT/enhancer-binding proteins in the differential expression of cyclo-oxygenase-2 in normal and neoplastic tissues. J Biol Chem 1998; 273:27686-27694.
83. Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclo-oxygenase-2 gene expression by p53. Biol Chem 1999; 274:10911-10915.
84. Ananthaswamy HN, Ullrich SE, Mascotto RE, Fourtanier A, Loughlin SM, Khaskina P, Bucana CD, Kripke ML. Inhibition of solar simulator-induced p53 mutations and protection against skin cancer development in mice by sunscreens. J Invest Dermatol 1999; 112:763-768.
85. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 1998; 58:2929-2934.
86. Dunn J, Garde J, Dolan K, Gosney JR, Sutton R, Meltzer SJ, Field JK. Multiple target sites of allelic imbalance on chromosome 17 in Barrett's oesophageal cancer. Oncogene 1999; 18:987-993.
87. Tetsuka T, Baier LD, Morrison AR. Antioxidants inhibit interleukin-1-induced cyclooxygenase and nitric-oxide synthase expression in rat mesangial cells. Evidence for post-transcriptional regulation. J Biol Chem 1996; 271:11689-11693.
88. Chinery R, Beauchamp RD, Shyr Y, Kirkland SC, Coffey RJ, Morrow JD. Antioxidants reduce cyclooxygenase-2 expression, prostaglandin production, and proliferation in colorectal cancer cells. Cancer Res 1998; 58:2323-2327.
89. Sheng GG, Shao J, Sheng H, Hooton EB, Isakson PC, Morrow JD, Coffey RJ Jr, DuBois RN, Beauchamp RD. A selective cyclooxygenase 2 inhibitor suppresses the growth of H-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997; 113:1883-1891.
90. Sheng H, Williams CS, Shao J, Liang P, DuBois RN, Beauchamp RD. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J Biol Chem 1998; 273:22120-22127.
91. Kelley DJ, Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Ramonetti JT, Dannenberg AJ. Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis 1997; 18:795-799.
92. Huet-Hudson YM, Chakraborty C, De SK, Suzuki Y, Andrews GK, Dey SK. Estrogen regulates the synthesis of epidermal growth factor in mouse uterine epithelial cells. Mol Endocrinol 1990; 4:510-523.
93. Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 1998; 83:2192-2198.
94. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996; 56:5125-5127.
95. Xiao CW, Liu JM, Sirois J, Goff AK. Regulation of cyclooxygenase-2 and prostaglandin F synthase gene expression by steroid hormones and interferon-tau in bovine endometrial cells. Endocrinology 1998; 139:2293-2299.
96. Shoda T, Hatanaka K, Saito M, Majima M, Ogino M, Harada Y, Nishijima M, Katori M, Yamamoto S. Induction of cyclooxygenase type-2 (COX-2) in rat endometrium at the peak of serum estradiol during the estrus cycle. Jpn J Pharmacol 1995; 69:289-291.
97. Chang CC, Noll WW, Nutile-McMenemy N, Lindsay EA, Baldini A, Chang W, Chang TY. Localization of acyl coenzyme A:cholesterol acyltransferase gene to human chromosome 1q25. Somat Cell Mol Genet 1994; 20: 71-74.
98. Lipsky PE. Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed? J Rheumatol 1999; 26 Suppl 56:25-30.
99. Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM, Dey SK. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91:197-208.
100. Han SW, Lei ZM, Rao CV. Up-regulation of cyclooxygenase-2 gene expression by chorionic gonadotropin during the differentiation of human endometrial stromal cells into decidua. Endocrinology 1996; 137:1791-1797.
101. McKanna JA, Zhang MZ, Wang JL, Cheng H, Harris RC. Constitutive expression of cyclooxygenase-2 in rat vas deferens. Am J Physiol 1998; 275:R227-233.
102. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110:1259-1262.
103. Fukutake M, Nakatsugi S, Isoi T, Takahashi M, Ohta T, Mamiya S, Taniguchi Y, Sato H, Fukuda K, Sugimura T, Wakabayashi K. Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 1998; 19:1939-1942.
104. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14:1493-1497.
105. Kawamori T, Rao CV, Seibert K, Reddy BS. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58:409-412.
106. Yoshimi N, Kawabata K, Hara A, Matsunaga K, Yamada Y, Mori H. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymetane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res 1997; 88:1044-1051.
107. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of cyclooxygenase-2 mRNA by prostaglandin E2 in human prostate carcinoma cells. Br J Cancer 1997; 75:1111-1118.
108. Tjandrawinata RR, Hughes-Fulford M. Up-regulation of cyclooxygenase-2 by product-prostaglandin E2. Adv Exp Med Biol 1997; 407:163-170.
109. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells over-expressing prostaglandin endoperoxide synthase 2. Cell 1995; 83:493-501.
110. Guilford P. E-cadherin downregulation in cancer: fuel on the fire? MoI Med Today 1999; 5:172-177.
111. Piazza GA, Rahm AL, Krutzsch M, Sperl G, Paranka NS, Gross PH, Brendel K, Burt RW, Alberts DS, Pamukcu R, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55:3110-3116.
112. Morita I, Schindler M, Regier MK, Otto JC, Hori T, DeWitt DL, Smith WL. Different intracellular locations for prostaglandin endoperoxide II synthase-1 and -2. J Biol Chem 1995; 270:10902-10908.
113. Narko K, Ristimaki A, MacPhee M, Smith E, Haudenschild CC, Hla T. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J Biol Chem 1997; 272:21455-21460.
114. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolatetal release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A 1997; 94:657-662.
115. Kinoshita T, Takahashi Y, SakashitaT, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenase 1 and 2 in human colon carcinoma cells. Biochem Biophys Acta 1999; 1438:120-130.
116. Battu S, Rigaud M, Beneytout JL. Resistance to apoptosis and cyclooxygenase-2 expression in a human adenocarcinoma cell line HT29 CL.19A. Anticancer Res 1998; 18:3579-3583.
117. Subbaramaiah K, Telang N, Bansal MB, Weksler BB, Dannenberg AJ. Cyclooxygenase-2 gene expression is upregulated in transformed mammary epithelial cells. Ann N Y Acad Sci 1997; 833:179-185.
118. Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 1997; 88:600-604.
119. Elder DJ, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997; 3:1679-1683.
120. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, DuBois RN. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 1998; 19:2195-2199.
121. Hida T, Leyton J, Makheja AN, Ben-Av P, Hla T, Martinez A, Mulshine J, Malkani S, Chung P, Moody TW. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs. Anticancer Res 1998; 18:775-782.
122. Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL. The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 1999; 81:101-107.
123. Zhu GH, Wong BC, Eggo MC, Ching CK, Yuen ST, Chan EY, Lai KC, Lam SK. Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc. Br J Cancer 1999; 79:393-400.
124. Liu XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58:4245-4249.
125. Simmons DL, Hotting RM, Robertson PM, Madsen ML, Vane JR. Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid anti-inflammatory drugs. Proc Natl Acad Sci U S A 1999; 96:3275-3280.
126. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93:705-716. Published erratum appears in Cell 1998, 94, following p 271.
127. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997; 94:3336-3340.
128. Kitamura Y, Morita I, Nihei Z, Mishima Y, Murota S. Effect of IL-6 on tumor cell invasion of vascular endothelial monolayers. Surg Today 1997; 27:534-541.
129. Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 1997; 17:(1A)337-342.
130. Fosslien E. Human uterine leiomyoma cells: Growth responses to epidermal growth factor and transforming growth factor beta. Ann Clin Lab Sci 1997; 27:318-319.
131. Hsu S, Huang F, Hafez M, Winawer S, Friedman E. Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression. Cell Growth Differ 1994; 5:267-275.
132. Picon A, Gold LI, Wing J, Cohen A, Friedman E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1. Cancer Epidemiol Biomarkers Prev 1998; 7:497-504.
133. Rioux N, Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res 1998; 58:5354-5360.
134. Castonguay A, Rioux N, Duperron C, Jalbert G. Inhibition of lung tumorigenesis by NSAIDs: a working hypothesis. Exp Lung Res 1998; 24:605-615.
135. Wallace JL, Reuter BK, McKnight W, Bak A. Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI safe? J Clin Gastroenterol 1998; 27(Suppl 1);S28-34.
136. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Tak-eto MM. Suppression of intestinal polyposis in APC delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87:803-809.
137. Taketo MM. COX-2 and colon cancer. Inflamm Res 1998; 47 (Suppl 2):S112-116.
138. Ritland SR, Gendler SJ. Chemoprevention of intestinal adenomas in the APC Min mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression. Carcinogenesis 1999; 20:51-58.
139. Mahmoud NN, Bilinski RT, Churchill MR, Edelmann W, Kucherlapati R, Bertagnolli MM. Genotype-phenotype correlation in murine APC mutation: differences in enterocyte migration and response to sulindac. Cancer Res 1999; 59:353-359.
140. Kovacs G. Abnormalities of chromosome No. 1 in human solid malignant tumours. Int J Cancer 1978; 21:688-694.
141. Rowley JD. Abnormalities of chromosome No. 1: significance in malignant transformation. Virchows Arch B Cell Pathol 1978; 29:139-144.
142. Battu S, Chable-Rabinovitch H, Rigaud M, Beneytout JL. Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A. Anticancer Res 1998; 18:2397-2403.
143. Spirio LN, Dixon DA, Robertson J, Robertson M, Barrows J, Traer E, Burt RW, Leppert MF, White R, Prescott SM. The inducible prostaglandin biosynthetic enzyme, cyclooxygenase 2, is not mutated in patients with attenuated adenomatous polyposis coli. Cancer Res 1998; 58:4909-4912.
144. Charpigny G, Reinaud P, Tamby JP, Creminon C, Guillomot M. Cyclooxygenase-2 unlike cyclooxygenase-1 is highly expressed in ovine embryos during the implantation period. Biol Reprod 1997; 57:1032-1040.
145. Olson GE, Winfrey VP, Matrisian PE, Meiner MH, Hoffman LH. Specific expression of haptoglobin mRNA in implantation-stage rabbit uterine epithelium. J Endocrinol 1997; 152:69-80.
146. Cid MC, Grant DS, Hoffman GS, Auerbach R, Fauci AS, Kleinman HK. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J Clin Invest 1993; 91:977-985.
147. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol 1995; 159:113-160.
148. Hamilton LC, Mitchell JA, Tomlinson AM, Warner TD. Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal anti-inflammatory drug efficacy. FASEB J 1999; 13:245-251.
149. Tay A, Simon JS, Squire J, Hamel K, Jacob HJ, Skorecki K. Cytosolic phospholipase A2 gene in human and rat: chromosomal localization and polymorphic markers. Genomics 1995; 26:138-141.
150. Praml C, Amler LC, Dihlmann S, Finke LH, Schlag P, Schwab M. Secretory type II phospholipase A2 (PLA2G2A) expression status in colorectal carcinoma derived cell lines in normal colonic mucosa. Oncogene 1998; 17:20009-20012.
151. Longo WE, Grossmann EM, Erickson B, Panesar N, Mazuski JE, Kaminski DL. The effect of phospholipase A2 inhibitors on proliferation and apoptosis of murine intestinal cells. J Surg Res 1999; 84:51-56.
152. Kamitani H, Geller M, Eling T. Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation. J Biol Chem 1998; 273:21569-21577.
153. Tang DG, Chen YQ, Honn KV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci USA 1996; 93:5241-5246.
154. Tang DG, Guan KL, Li L, Honn KV, Chen YQ, Rice RL, Taylor JD, Porter AT. Suppression of W256 carcinosarcoma cell apoptosis by arachidonic acid and other polyunsaturated fatty acids. Int J Cancer 1997; 72:1078-1087.
155. Rouzer CA, Ford-Hutchinson AW, Morton HE, Gillard JW. MK886, a potent and specific leukotriene biosynthesis inhibitor, blocks and reverses the membrane association of 5-lipoxygenase in ionophore-challenged leukocytes. J Biol Chem 1990; 265:1436-1442.
156. Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95:13182-13187.
157. Anderson KM, Seed T, Vos M, Mulshine J, Meng J, Alrefai W, Ou D, Harris JE. 5-Lipoxygenase inhibitors reduce PC-3 cell proliferation and initiate non-necrotic cell death. Prostate 1998; 37:161-173.
158. Ikawa H, Kamitani H, Calvo BF, Foley JF, Eling TE. Expression of 15-lipoxygenase-1 in human colorectal cancer. Cancer Res 1999; 59:360-366.
159. Hong SH, Avis I, Vos MD, Martinez A, Treston AM, Mulshine JL. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res 1999; 59:2223-2228.
160. Mandell BF. COX 2-selective NSAIDs: biology, promises, and concerns. Cleve Clin J Med 1999; 66:285-292.